학술논문

Combined Oral Contraceptives and Vascular Thrombosis: A Single-Center Experience.
Document Type
Academic Journal
Author
AlSheef M; Internal Medicine and Thrombosis, Medical Specialties Department, King Fahad Medical City, Riyadh, SAU.; Abuzied Y; Nursing Department, Rehabilitation Hospital, King Fahad Medical City, Riyadh, SAU.; Alzahrani GR; Pharmacy Department, Prince Sultan Military Medical City, Riyadh, SAU.; AlAraj N; Pharmacy Services Department, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, SAU.; AlAqeel N; Pharmaceutical Care Department, King Abdullah Specialist Children's Hospital, King Abdulaziz Medical City, Riyadh, SAU.; Aljishi H; Epidemiology and Public Health, King Fahad Medical City, Riyadh, SAU.; Alomar MJ; Pharmacy Services Administration, King Fahad Medical City, Riyadh, SAU.; Zaidi ARZ; Internal Medicine, Medical Specialties Department, King Fahad Medical City, Riyadh, SAU.; Alarfaj OM; Pharmacy Services Administration, King Fahad Medical City, Riyadh, SAU.
Source
Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2168-8184
Abstract
Background Combined oral contraceptives (COCs) are frequently prescribed for contraception, to regulate ovulation and treat endometriosis, and to control menopausal symptoms. A major risk of hormonal contraceptives is vascular thrombosis. Methods A retrospective chart review of female patients with deep vein thrombosis (DVT), pulmonary embolism (PE), or other sites of thrombosis or emboli seen in the thrombosis clinic of the department of internal medicine at a tertiary care hospital in Saudi Arabia between March 2010 and February 2015 was performed to identify and characterize which women were taking COCs. Results Of 1,008 patients treated for DVT, PE, or other sites of thrombosis or emboli, 100 (9.9%) were taking COCs. Venous (98%) and arterial (2%) thromboses were seen. Overall, 62% of the patients experienced a DVT and 26% pulmonary emboli, and 20% of the patients experienced unusual sites of thrombosis. Furthermore, 53% were obese or morbidly obese. The incidence of venous thrombosis was the highest during the first year of COC use (73%). Of the patients, 8% had thrombophilia. Conclusion This study characterizes Saudi women with thrombotic events taking COCs and identifies risk factors, including unusual sites of thrombosis. Most patients experienced the vascular event during the first year of taking COCs. Age of 40-50 years, obesity, and thrombophilia were the commonly observed risk factors.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2022, AlSheef et al.)